Qezzaqar withdrawal: what a pulled EU sarcoma filing after a negative CHMP opinion means

What happened

CATS Consultants GmbH has withdrawn its EU marketing authorisation application for Qezzaqar (catequentinib), a sarcoma treatment. According to EMA's record, published on 13 November 2026, the withdrawal took effect on 30 October 2026. The CHMP had previously issued a negative opinion, and the company had asked for that opinion to be re-examined. The application was pulled before the re-examination was completed, so the committee never issued a final re-examined opinion.

The record does not say why the company withdrew, and it does not say what the CHMP's objections were. It also does not say whether CATS plans to resubmit in the EU, to file elsewhere, or to continue development. Those points are not yet known, and anything beyond the procedural sequence would be speculation.

Why the sequence matters

A negative CHMP opinion is not the end of the road. Under EU procedure, an applicant can ask for re-examination, submit detailed grounds, and have the committee look at the opinion again, usually with a different set of rapporteurs. Re-examination is the formal route for challenging a refusal recommendation on the existing dossier.

Withdrawing mid-way is a different outcome from losing a re-examination. If the CHMP confirms a negative opinion, the Commission moves toward a refusal decision. A withdrawal ends the procedure without that final step. EMA typically publishes a public assessment for withdrawn applications, so the committee's reasoning may become visible in due course. Regulatory teams should read that document when it appears, because it is the clearest guide to how the agency viewed the evidence.

Whatever the company's motives, the case is a reminder that requesting re-examination does not commit a sponsor to seeing it through. Sponsors can reassess their position after the request is lodged.

The wider picture on the same day

The same day's records show how different regulatory outcomes can look for different products. Roche's Gazyvaro (obinutuzumab) received a positive CHMP opinion as add-on therapy for adults with autoantibody-positive, moderate-to-severe, active systemic lupus erythematosus despite standard therapy, based on phase III ALLEGORY data. Novartis received a positive CHMP opinion for Cosentyx (secukinumab) in adolescents aged 12 and over with moderate-to-severe hidradenitis suppurativa who responded inadequately to conventional systemic therapy. Both now await a European Commission decision.

The US records offer a contrast in how sponsors manage regulatory risk. NeOnc will use an early January 2027 Type B meeting to test whether Phase 2a data can support a 505(b)(2) application for intranasal NEO100 in recurrent IDH-mutant grade 4 astrocytoma. Cingulate expects to resubmit its CTx-1301 NDA between December 2026 and January 2027, after FDA raised manufacturing questions in a June complete response letter. Intellia's BLA for lonvoguran ziclumeran has priority review, a 10 March 2027 goal date, and no currently planned advisory committee, according to the company.

These cases are not comparable on the science, and the records do not link them to Qezzaqar. What they share is that each sponsor is using a formal procedural step, whether a pre-submission meeting, a resubmission or a re-examination, to shape the outcome. The Qezzaqar record shows one of those steps ending in a withdrawal.

Who is affected

Directly affected is CATS Consultants, which has no EU authorisation for Qezzaqar. Beyond that, the records do not describe any patient access programmes, trials or national procedures, so their status is unknown.

For other sponsors, particularly smaller companies with oncology filings in the EU, the case is a prompt to plan for the post-opinion phase early. Re-examination requires a rapid, well-argued response within fixed timelines. Companies should decide beforehand what new analysis, if any, they can credibly present, and what a withdrawal would mean for any later filing.

For regulatory intelligence and market-access teams tracking competitors, the withdrawal removes Qezzaqar from the near-term EU pipeline in sarcoma. The records do not say how many alternatives exist or how the product would have been positioned, so no market conclusions can be drawn.

What to watch

First, EMA's public documentation on the withdrawal, which would clarify the CHMP's concerns. Second, any statement from CATS on future plans, including resubmission. Third, whether the stated reasons for the negative opinion bear on how the CHMP views similar evidence packages in sarcoma or other rare cancers. None of this is known yet, and teams should avoid reading across until the assessment is published.